Gilead Sciences

News

Gilead to buy liver disease specialist CymaBay for $4.3bn

Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC),

News

Gilead drops CD47 drug magrolimab for blood cancers

Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical t

News

FDA launches wide probe into CAR-T therapy safety

The FDA has announced it will start an investigation into the safety of CAR-T therapies, after becoming concerned that they may be linked to the development of T-cell canc

News

Alfasigma to buy Galapagos’ JAK drug for up to €170m

Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Ita

News

Gilead plans European trial of twice-yearly HIV PrEP drug

Gilead Sciences has said it will soon start a clinical trial in Europe of its twice-yearly HIV injection Sunlenca for pre-exposure prophylaxis (PrEP), a potential successo

News

ViiV’s injectable HIV PrEP drug Apretude gets EU okay

People in the EU who need access to pre-exposure prophylaxis (PrEP) for HIV could soon have a new option with fewer doses after the European Commission approved ViiV Healt

Gilead to buy liver disease specialist CymaBay for $4.3bn

Gilead drops CD47 drug magrolimab for blood cancers

FDA launches wide probe into CAR-T therapy safety

Alfasigma to buy Galapagos’ JAK drug for up to €170m

Gilead plans European trial of twice-yearly HIV PrEP drug

ViiV’s injectable HIV PrEP drug Apretude gets EU okay

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Gilead Sciences

Editor's Picks